Statistical findings were more consistent with the results of the descriptive analysis, with no significant difference in FGF21 levels between patients with and without sarcopenia [SMD = 0.31(95% CI, -0.42, 1.04); P = 0.41; I2 = 94%] (Fig. 3). This evidence concerns the gene FGF21 and sarcopenia.